Key Words: adhesion molecules Ⅲ nuclear factor B Ⅲ protease Ⅲ leukocyte adhesion C alpain is a ubiquitously expressed, cytosolic, Ca 2ϩ activated, neutral cysteine protease that consists of a large 80-kDa catalytic subunit and a small 30-kDa regulatory subunit. Two calpain isoforms, and m, are ubiquitously expressed and, thus, are found in the vascular wall, where they regulate important functions of endothelial 1 and smooth muscle cells. 2 Two recent studies have implicated calpain in the vascular pathology of Ang II by demonstrating a mechanistic role for calpain in smooth muscle cell homeostasis 2 and vascular remodeling. 3 Surprisingly, no study has addressed the role of calpain in the endothelial dysfunction of Ang II, albeit recent work has emphasized a key mechanistic role for the vascular endothelium in Ang II-induced pathology that affects the entire vascular wall. 4 Indeed, because of its strategic location between the blood compartment, the vascular wall, and the parenchyma of organ tissues the endothelium plays a very early mechanistic role in the initiation and progression of vascular disease, and related organ damage.
C alpain is a ubiquitously expressed, cytosolic, Ca 2ϩ activated, neutral cysteine protease that consists of a large 80-kDa catalytic subunit and a small 30-kDa regulatory subunit. Two calpain isoforms, and m, are ubiquitously expressed and, thus, are found in the vascular wall, where they regulate important functions of endothelial 1 and smooth muscle cells. 2 Two recent studies have implicated calpain in the vascular pathology of Ang II by demonstrating a mechanistic role for calpain in smooth muscle cell homeostasis 2 and vascular remodeling. 3 Surprisingly, no study has addressed the role of calpain in the endothelial dysfunction of Ang II, albeit recent work has emphasized a key mechanistic role for the vascular endothelium in Ang II-induced pathology that affects the entire vascular wall. 4 Indeed, because of its strategic location between the blood compartment, the vascular wall, and the parenchyma of organ tissues the endothelium plays a very early mechanistic role in the initiation and progression of vascular disease, and related organ damage.
Several lines of research have now extensively demonstrated that upregulation of Ang II signaling causes endothelial dysfunction mainly via activation of the AT 1 R, even in the absence of significant changes in systemic blood pressure. The dysfunctional endothelium initiates and maintains vascular pathology by becoming abnormally adhesive to circulating leukocytes and leaky to plasma proteins, 2 processes responsible for vascular and organ tissue damage. Thus, activation of the Ang II/AT 1 R signaling pathway has been shown to: (1) upregulate endothelial cell adhesion molecules (eCAMs) in vitro, 5 as well as and in microcirculation of experimental animal models 6 ; (2) induce leukocyte-endothelium interactions 6 ; and (3) increase vascular permeability. 7 Preclinical and clinical data demonstrate that pharmacological inhibition of the renin-angiotensin system (RAS) attenuates endothelial dysfunction and cardiovascular events independently of blood pressure lowering effects. 8 Of note, AT 1 R blockers (ARBs) attenuate expression of endothelial cell adhesion molecules, 9 leukocyte-endothelium interactions, 10 and vascular permeability. 11 Despite intensive research, the precise molecular mechanisms by which Ang II/AT 1 R signaling disrupts critical components of endothelial function remain largely unknown, which obstructs full therapeutic exploration of RAS inhibition in vascular disease.
We hypothesized that stimulation of Ang II/AT 1 R signaling induces endothelial dysfunction in part via activation of the endothelial calpain system. Accordingly we studied the role of -and m-calpain in the leukocyte-endothelium interaction and vascular permeability induced by Ang II/AT1 signaling. Using pharmacological and genetic approaches, we demonstrate that Ang II upregulates endothelial calpain activity via AT 1 R signaling thus causing a distinct endothelial inflammatory phenotype characterized by increased leukocyte-endothelium interactions and albumin permeability. We also demonstrate that inhibition of calpain activity is an important molecular mechanism of the vascular protective action of ARBs.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org
Ang II Infusion Protocols
All experimental procedures were approved by Temple University IACUC and performed according to the NIH guidelines for the use of experimental animals. Subpressor concentrations of Ang II were systemically delivered to randomly selected groups of rats or mice using Alzet osmotic minipumps implanted subcutaneously (Model 2002; ALZA Scientific Products, Mountain View, CA). Pumps were filled with either saline or with Ang II at the concentration of 20 ng/kg per minute or 500 ng/kg per minute, for rat or mice, respectively. All pumps delivered saline or Ang II for 14 days. Previous studies in the species rat have demonstrated that infusion of 20 ng/kg per minute induces endothelial dysfunction with inflammation in the absence of significant changes in systemic blood pressure. 12 Because considerably higher doses of Ang II are required to elicit vascular responses in C57BL/6J mice, 13 we used the higher dose of 500 ng/kg per minute Ang II.
In Vivo Endothelial Function
We used quantitative intravital microscopy of the mesenteric microcirculation to measure important indices of endothelial function such as vessel diameter, venular wall shear rates, leukocyte rolling, adhesion, and extravasation, and vascular permeability. The microcirculation of the rat mesentery was used for these studies because it is highly amenable to intravital microscopy and because it expresses a typical inflammatory phenotype in response to very low, subpressor concentration of Ang II. 14 
Data Analysis
Data are presented as meansϮSEM and compared by ANOVA with post hoc analysis by Fisher's corrected t test. Probabilities of 0.05 or less were considered statistically significant.
Results

Ang II Infusion Increases Calpain in the Vasculature via AT 1 R Signaling
To study the relationship between Ang II and calpain, we first measured calpain activity in extracts of vascularized sections of mesenteries isolated from rat and mice infused with subpressor doses of Ang II for 14 consecutive days. Calpain activity in tissue extracts was measured using the fluorogenic calpain substrate Succ-LLVY-AMC. We found evidence of 2-fold increase in vascular calpain activity under these experimental conditions (Figure 1 ). Treatment of Ang IIinfused animals with 10 mg/kg per day of the AT 1 R blocker losartan attenuated calpain activity to values found in control animals ( Figure 1 ). Moreover, infusion of Ang II to mice deficient in AT1 A receptor, the major mouse AT 1 R isoform and the closest murine homolog to the single human AT1, 15 failed to increase calpain activity in the vasculature thus demonstrating the obligatory role of the AT 1 R in the process of calpain activation by Ang II ( Figure 1B) .
Comparable results were obtained following pharmacological inhibition of calpain in Ang II-infused animals ( Figure 1 ). Thus, a 5-day treatment with either 140 g/kg per day ZLLal or 1 mg/kg per day PD150, 2 selective calpain inhibitors, each with different molecular structure and mechanism of action, normalized calpain activity in the vasculature.
We next measured calpain activity in the intact microcirculation of live rats infused with Ang II. For these studies, we coupled the fluorescent based assay of calpain activity described in Figure 1 with in vivo microscopy of mesenteric postcapillary venules, which are microvessels comprised only by a layer of endothelial cells, a basement membrane, and pericytes. 16 The advantage of this approach over the biochemical one described above is that it allows for simultaneous quantification and spatial localization of active calpains within the vascular endothelium of the 
observed microcirculation in vivo. In fact, the results obtained with the mesenteric tissue homogenates described in Figure 1 could in theory have been contaminated with vascular smooth muscle cells which also express calpain. 2 Fluorescent staining clearly demonstrated that following Ang II infusion the wall of postcapillary venules experiences increased calpain activity ( Figure 2B ). Quantification of the fluorescent staining revealed a 3-fold increase from control in calpain activity in postcapillary venules of Ang II-infused rats, which was attenuated to control levels following pharmacological inhibition of either AT 1 R or calpain (PϽ0.05; Figure 2 , bar graph to the left). These results are consistent with the biochemical analysis for calpain activity reported in Figure 1 and they further confirm that upregulation of Ang II/AT 1 R signaling increases calpain activity in the endothelium of postcapillary venules.
Identification of the Calpain Isoform Implicated in the Endothelial Dysfunction of Ang II/AT 1 R Signaling
Two calpain isoforms, namely -calpain and m-calpain, are constitutively expressed in endothelial cells. 1 To investigate the effect of Ang II/AT 1 R signaling on -and m-calpain activity in vivo, we measured expression levels of the N-terminal domain of the calpain large 80 kDa subunit. On activation, calpains undergo autoproteolysis with removal of the 9 to 14 amino acids from the N-terminal domain of the large 80 kDa subunit. 17 Accordingly, m-and -calpain autoproteolysis/activation levels in freshly isolated vascular segments of mesenteric tissue from all groups of rats were assessed by immunoblot analysis using primary antibodies to their respective N-terminal domains. We found increased proteolytic activity of -calpain only in Ang II-infused rats, as demonstrated by an average 70% loss in N-terminal Total -calpain content was quantified using a primary antibody against the stable domain IV of the large subunit, which recognizes both unautolyzed and autolyzed (ie, active) -calpain. No significant differences in total -calpain expression were found in all experimental groups rats ( Figure 3 , middle lanes of A and B and bar graphs), which indicates that Ang II did not change significantly the transcriptional regulation of calpain, at least in the time frame of our experimental conditions. In contrast, the proteolytic activity of m-calpain was not increased by Ang II infusion as demonstrated by lack of changes in m-calpain N-terminal domain expression level (Online Figure I, A and B) . Parallel genetic studies in vitro were undertaken to further confirm -calpain as the target of Ang II/AT 1 R signaling in the vascular endothelium. Thus, we used small interfering (si)RNA technology to knockdown -calpain in primary cultures of mesenteric microvascular endothelial cells (MMECs), freshly isolated from donor control rats. The siRNA used in this study effectively reduced -calpain expression levels (Figure 4 , immunoblot) without affecting expression levels of the m-calpain isoform (data not shown). Calpain activity in attached MEC was then measured using the fluorescent assay described above. Data shown in Figure  4 demonstrate that MMECs exposed to 10 nmol/L Ang II for 6 hours experience a 1.5 fold increase in calpain activity. The calpain-activating actions of Ang II were abolished by -calpain siRNA treatment, as well as following inhibition of either the AT 1 R or calpain with losartan and ZLLal, respectively ( Figure 4 ). Taken together, the in vivo and in vitro data reported in Figures 1 through 4 strongly demonstrate that Ang II/AT 1 R signaling increases -calpain activity in the vascular endothelium. They also suggest that -calpain may represent an important target of the pleiotropic actions of AT 1 R blockers in cardiovascular disease.
Ang II-Induced Calpain Activation Causes Endothelial Dysfunction With Increased Leukocyte-Endothelium Interactions and Disruption of the Endothelial Cell Barrier
To study the functional implications of calpain activation induced by the Ang II/AT 1 R, we measured leukocyte-endothelium interactions and albumin permeability by intravital microscopy. As shown in A of Figure 2 and quantified in Figure 5 , the venular endothelium of Ang II-infused rats experienced increased adhesiveness to circulating leukocytes. Specifically, we found evidence of a 3-fold increase in leukocyte rolling and a 4-fold increase in both leukocyte adhesion and extravasation in mesenteric postcapillary venules of Ang II-infused rats compared to control rats receiving saline ( Figure 5A through 5C ). Leukocyte rolling, adhesion and extravasation were all reduced following treatment with the either the AT 1 R blocker losartan, the calpain inhibitor ZLLal, or the NF-B inhibitor PDTC ( Figure 5 ). Furthermore, Ang II failed to increase leukocyte adhesion in the mesenteric microcirculation of -calpain deficient mice (Online Figure II) .
Parallel ex vivo experiments with aortas and leukocytes isolated from wild-type C57BLK mice demonstrated an essential role for the vascular endothelium in the proadhesive action of Ang II (Online Figure III, A) . Specifically, when Ang II-stimulated aortic segments were incubated with unstimulated leukocytes a significantly high number of leukocytes adhered to the aortic endothelium (PϽ0.05 versus control unstimulated aortas/unstimulated leukocytes). In contrast, no difference from control was observed following incubation of unstimulated aortas with Ang II-stimulated leukocytes (PϾ0.05), even though we found evidence of calpain-dependent increase in CD11b expression in circulating leukocytes of Ang II-infused rats (Online Figure IV) . The increased adhesiveness of Ang II-stimulated aortas was also prevented by incubation of the aortic tissue with losartan or ZLLal (Online Figure III, A) .
Additional mechanistic studies were undertaken to dissect the contribution of endothelial-expressed and leukocyteexpressed calpains in these studies. The results obtained demonstrated that endothelial-expressed calpain and not leukocyte-expressed calpain was the target of Ang II under our experimental conditions. Specifically, Ang II failed to increase the adhesion of leukocytes isolated from wild-type mice to the aortic endothelium of -calpain deficient mice as well as of mice overexpressing the endogenous inhibitor of calpain, calpastatin (Online Figure III, B) . In contrast, increased leukocyte adhesion to Ang II was observed when aortas isolated from wild-type mice were incubated with leukocytes isolated from -calpain deficient mice or calpastatin overexpressing mice (Online Figure III, B) . These data are , and extravasation (C) were studied in all experimental groups of rats by bright field intravital microscopy and expressed as the number of leukocytes/min, leukocytes/100-m vessel length, and leukocytes/1000 m 2 extravascular space, respectively. Ang II increases leukocyte endothelium interactions in the microcirculation, which were reduced similarly by losartan, ZLLal or PDTC treatment. Bars represent meansϮSEM, and numbers at the base of the bars represent the number of rats studied in each group.
in agreement with data on leukocyte adhesion obtained by intravital microscopy and they demonstrate that in the setting of increased Ang II/AT 1 R signaling, the vascular endothelium develops a widespread proadhesive phenotype affecting both large conduit vessels and the microcirculation.
We also used fluorescent intravital microscopy of postcapillary venules to measure albumin leakage, another established marker of endothelial function. Data reported in Figure  6 demonstrate that Ang II disrupts the physiological endothelial cell barrier as demonstrated by the increased albumin leakage found in Ang II-infused rats. This permissive action of Ang II on albumin permeability was abolished by treatment of Ang II-infused rats with either losartan or ZLLal ( Figure 6 ).
These functional results were observed in the absence of significant changes in mean arterial blood pressure, vessel diameter, venular shear rates, and total leukocyte blood counts (Online Table I ).
Taken together, these data first demonstrate that endothelial expressed calpains are, at least in part, responsible for the endothelial inflammatory actions Ang II/AT 1 R signaling in the cardiovascular system.
Ang II/Calpain Signaling Upregulates Endothelial eCAMs via Downregulation of IB␣
To investigate the molecular mechanism(s) responsible for the dysfunctional endothelial phenotype induced by Ang II-mediated -calpain activation, we studied expression levels of the cell adhesion molecules intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and E-selectin both in vivo and in vitro. Figure 7 illustrates ICAM-1 expression levels in all experimental groups of rats studied by immunohistochemistry. Thus, we found a 5-fold increase in ICAM-1 expression in the microcirculation of Ang II-infused rats compared to control rats given saline. Consistent with the functional data reported above, ICAM-1 expression was attenuated by treatment with losartan, ZLLal or the NF-B inhibitor PDTC (Figure 7 , left bar graph). Similar results were observed for VCAM-1 and E-selectin (Online Figure V) .
Flow cytometric studies further confirmed the increased ICAM-1 expression levels in MECs exposed to 10 nmol/L Ang II for 6 hours, a phenomenon that was prevented by either inhibition of AT 1 R, calpain, or NF-B with losartan, ZLLal, and PDTC, respectively ( Figure 7, right bar graph) . Furthermore, The effect of Ang II on eCAMs expression were also found to be largely -calpain dependent as demonstrated by lack of ICAM-1 upregulation following siRNA depletion Figure 6 . Elevated Ang II/AT 1 R signaling increases albumin permeability. The average permeability index to Texas red-labeled albumin was calculated during intravital microscopy in single mesenteric postcapillary venules of all experimental groups of rats. A 2-week exposure of the mesenteric microcirculation to a low, subpressor dose of Ang II increases albumin permeability via AT 1 R signaling and in a calpain-dependent manner. Thus, both losartan and the calpain inhibitor ZLLal attenuated albumin permeability in Ang II-injected rats. Data are expressed as the meansϮSEM, and numbers at the base of the bars represent the number of rats studied in each group. of -calpain (Figure 7 , right bar graph). These data correlate with the antiadhesive effect of AT 1 R blockade and calpain inhibition on leukocyte-endothelium interactions reported above.
In the vascular endothelium, ICAM-1, VCAM-1, and E-selectin are largely regulated by NF-B, an inflammatory nuclear transcription factor that it sequestered inactive in the cytoplasm by the inhibitor protein IB␣. Accordingly, we measured IB␣ expression levels in vascular sections of the mesentery from all experimental groups of rats. Data reported in Figure 8 demonstrate that the microcirculation of Ang II-infused rats experiences loss of IB␣, which can be prevented by pharmacological inhibition of either AT 1 R or calpain with losartan and ZLLal, respectively. Taken together, these data demonstrate that Ang II/AT 1 R signaling causes IB␣ degradation in part via increased calpain activity and they provide a novel mechanism by which Ang II/AT 1 R signaling induces transcription of inflammatory mediators in the dysfunctional endothelium.
Discussion
The present work, to our knowledge, is the first to uncover the role of the cytosolic protease calpain in the endothelial dysfunction associated with elevated Ang II signaling. We show that subpressor doses of Ang II selectively activate the endothelial expressed -calpain isoform, a process that induces a distinct endothelial inflammatory phenotype. Importantly, we show that -calpain is a molecular target of AT 1 R signaling, which may also help uncover new mechanism(s) of the pleiotropic actions of ARBs.
Disruption of the regulatory functions of the vascular endothelium results in multiple maladaptive modifications, including making the endothelium hyper adhesive to circulating leukocytes and leaky to macromolecules. Studies in research animals and humans have clearly linked Ang II/ AT 1 R signaling to endothelial dysfunction, independently of its vasopressor actions. In agreement with our results, others have demonstrated that nanomolar concentrations of Ang II acutely increase leukocyte-endothelium interactions 18 and vascular permeability 19 in the rat microcirculation without affecting local or systemic hemodynamic. Leukocyte-endothelium interactions and vascular permeability are 2 fundamental functions of the endothelium that are also crucial to the homeostasis of organ tissues, including the vascular wall itself. In fact, leukocyte trafficking is mechanistically important in vascular pathology. Extravasation of proteins into the adjacent interstitial compartment modifies the composition of the interstitium, which disrupts traffic of fluid and vital substrates to the cellular mass, and the removal of waste products. 20 Accordingly, full understanding of the molecular mechanisms by which Ang II increases leukocyte-endothelium interaction and vascular permeability becomes crucial for the management of vascular disease and related organ damage. With most data indirectly derived from studies using pharmacological inhibitors of the RAS, our understanding of the primary cellular pathways(s) responsible for the endothelial inflammatory action of Ang II remains largely elusive, which hinders development of new therapeutic strategies. Our present data are the first to identify in the calpain system a direct molecular effector of the endothelial Ang II/AT 1 R signaling pathway. This novel working hypothesis is supported by data in the scientific literature. Calpains are cytosolic proteases that require calcium for their activation and function. 17 Of interest, published data have demonstrated that in cultured endothelial cells Ang II increases intracellular calcium concentrations via activation of AT 1 R. 21 The detailed signaling pathway(s) by which activation of the AT 1 R leads to increased endothelial calpain activity with subsequent leukocyte adhesion remains unknown. Data in the literature have highlighted a role for the calcitonin gene-related peptide (CGRP) in the leukocyte adhesion associated with activation of the AT 1 R, 22 which may suggest a role for CGRP in these studies. We found that Ang II selectively activates the -calpain isoform, but not the m-calpain isoform. This result is in agreement with recent studies demonstrating a role for -calpain in the homeostasis of the vascular wall 2, 3, 23 and it is compatible with the knowledge that only the Ca 2ϩ concentrations required by autolyzed -calpain are in the physiological range, whereas the Ca 2ϩ concentrations required by m-calpain are much higher than those found in living cells. 17 Nonetheless, the possibility that with chronic disease other vascular expressed calpain isoforms may also become deregulated should not be entirely excluded based on in vitro studies demonstrating a role for m-calpain in the microvascular endothelial toxicity induced by inflammatory media- tor. 24 Furthermore, evidence in the literature suggests the possibility of sequential activation of calpain isoforms. 17 Specific adhesion molecules expressed on the vascular endothelium and circulating leukocytes regulate leukocyteendothelium interactions in the cardiovascular system. In this study, we focused on the role of NF-B-regulated cell adhesion molecules such as ICAM-1, VCAM-1 and E-selectin. Despite intensive research, the molecular mechanisms by which Ang II/AT 1 R signaling upregulates NF-Bcontrolled eCAMs is not fully understood. Our in vitro and in vivo results first demonstrate a mechanistic role for -calpain in the process of eCAMs upregulation by Ang II. Interestingly, others have implicated calpains in the upregulation of eCAMs expression via NF-B. 25 We also found evidence of increased CD11b expression levels on the cell surface of blood resident leukocytes of Ang II-infused rats, although isolated leukocytes stimulated with Ang II failed to adhere the endothelium of control aortas in vitro. This result indicates that activation of endothelial expressed CAMs is necessary for the vascular inflammatory action of Ang II, which is consistent with published information demonstrating that Ang II-induced leukocyte-endothelium interactions can be largely abrogated by eCAMs blockade alone. 6 Albeit Ang II-induced upregulation of CD11b was also attenuated by calpain inhibition in our study, the overall impact of calpain inhibition on leukocyte function remains still controversial. Studies have reported increased leukocyte adhesion, polarization, and chemotaxis following inhibition of basal calpain activity in resting leukocytes. 26 In contrast, more recent reports demonstrate that inhibition of calpain activity reduces the adhesiveness and migratory properties of leukocytes primed by clinically relevant inflammatory stimuli. 23, 27 A recent study also supports a role for -calpain in neutrophilinduced ICAM clustering, a process important in leukocyte extravasation. 28 Overall, emerging views in the field consider activation of leukocyte-expressed calpains necessary for leukocyte expansion, a process central in leukocyte extravasation. 29 Relevant to the physiology of leukocyte-endothelium interactions, endothelial expressed calpains have been shown to influence the adhesive and migratory behavior of circulating leukocytes. 30 Conversely, adhesion of leukocytes initiates calcium signaling events that lead to activation of the endothelial calpain system, which in terms favors leukocyte transmigration in inflammation. 31 Further studies are clearly needed to understand how inhibition of the calpain system impacts the adhesive behavior of resting and primed leukocytes, both in the presence and absence of the vascular endothelium.
Leukocytes interact with the endothelium in a process that allows blood resident leukocytes to cross the barrier created by endothelial cells. This cellular migration can result in modifications of the vascular permeability that permit the nonphysiological transfer of macromolecules from the blood compartment to the vascular wall and peripheral tissue. Sumagin et al 32 have recently shown that vascular permeability alterations can be induced by endothelial expressed CAMs, such as ICAM-1, following ligation by rolling or adhering leukocytes. Interestingly, we also found that inhibition of -calpain prevents albumin permeability in microvascular networks inflamed by Ang II, which suggest a key role for the endothelial calpain system in this process. In the present study, we did not investigate whether the hyperpermeability of Ang II was secondary to adhering leukocytes or primarily driven by eCAMs-induced signaling. Because studies in this direction can provide additional therapeutic targets, further work should be undertaken to understand the primary contribution to vascular permeability of calpain-mediated eCAMs upregulation in disease states associated with elevated Ang II signaling.
The molecular mechanism by which Ang II upregulates eCAMs appears to be related to activation of the nuclear transcription factor NF-B. 33 In vitro studies have demonstrated increased activation of NF-B in response to Ang II in several cell types, including VSMCs and endothelial, glomerular, tubular, and mononuclear cells. 34 In vivo, increased NF-B activity and expression have been shown in the vasculature, heart, and kidneys of double transgenic rats and Ang II-infused wild-type rats. 35, 36 Nonetheless, the precise signaling pathway by which Ang II upregulates NF-B remains largely unknown. Interestingly, calpain is known to degrade the NF-B-inhibitory subunit IB␣, thus leading to NF-B activation. 37 Here, we report evidence of calpaindependent degradation of IB␣ in response to activation of Ang II/AT 1 R signaling in the rat vasculature, which uncovers a novel molecular mechanism by which Ang II upregulates NF-B activity and actions in the vascular wall.
Data in the literature have consistently shown that Ang II-induced vascular inflammation is largely mediated via stimulation of the AT 1 R. Relevant to the present study, the AT 1 R blockers, such as losartan, attenuate (1) leukocyte-endothelium interactions in Ang II-inflamed microvascular networks 38 ; (2) vascular permeability in experimental animal models 11 ; and (3) albuminuria in patients with cardiovascular disease. 39 However, the precise cellular targets of the endothelial pleiotropic actions of ARBs remain largely unknown. Our results strongly demonstrate a role for the endothelial calpain system in the beneficial vascular actions of ARBs. In fact, losartan prevented calpain activation both in vivo and in vitro, a result that was also confirmed in AT 1 R deficient mice. Furthermore, pharmacological blockade of calpain achieved a degree of endothelial protection which was comparable to that observed with losartan treatment in vivo. Thus, both losartan and the calpain inhibitor ZLLal stabilized IB␣ levels and prevented leukocyte-endothelium interactions and albumin permeability in the face of increased Ang II levels.
In summary, the present studies demonstrate that -calpain contributes to the development of Ang II-induced endothelial dysfunction. Specifically, inhibition of calpain activation attenuates leukocyte-endothelium interactions, albumin permeability, endothelial CAMs expression, and IB␣ degradation in Ang II-infused rats. Finally, these protective actions of calpain inhibition are related to inhibition of AT 1 R signaling, which demonstrate a mechanistic role for calpain in the pleiotropic actions of ARBs. Our studies may have important clinical implications in that they provide evidence for a novel molecular target in the treatment of Ang IImediated vascular disease.
